Monograph
L01XX02 - Asparaginase |
Not porphyrinogenic |
NP |
Rationale
Enzyme. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Asparaginase is an enzyme derived from Escherichia coli, that converts L-aspargine to aspartic acid and ammonia.
Therapeutic characteristics
Asparaginase is an antineoplastic agent used for induction of remission in acute lymphattic leucemia. It is administered as an intravenous administration. Common adverse reactions of asparaginase that can be confused with an acute porphyric attack are nausea, vomiting, depression, confusion and irritability. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Hepatic exposure
Not relevant.
Published experience
Uneventful use reported in one 16-year old female patient with PV (Samuels, 1984).
Similar drugs
References
# | Citation details | PMID |
---|---|---|
* | Scientific articles | |
1. | Chemotherapy in porphyria. S Afr Med J 1984; 65(23):924-6.
Samuels B, Bezwoda WR, et al. |
6587589 |
* | Drug reference publications | |
2. | McEvoy GK, editor. Asparaginase. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (07.06.10).
|
|
3. | Sweetman SC, editor. Martindale: The complete drug reference. Asparaginase. Pharmaceutical Press 2009.
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025